Each Olvion tablet contains 50 mg of sildenafil citrate.
Each tablet also contains 3.6 mg lactose monohydrate.
It also contains the following excipients: Microcrystalline cellulose, anhydrous calcium hydrogen phosphate, croscarmellose sodium, magnesium stearate, hypromellose, titanium dioxide (E171), lactose monohydrate and triacetin.
Pharmacology: Pharmacodynamics: Sildenafil, an oral therapy for erectile dysfunction, is the citrate salt of sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5).
Mechanism of Action: The physiologic mechanism of erection of the penis involves release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation.
Nitric oxide then activates the enzyme guanylate cyclase, which results in increased levels of cGMP, producing smooth muscle relaxation in the corpus cavernosum and allowing inflow of blood.
Sildenafil has no direct relaxant effect on isolated human corpus cavernosum but enhances the effect of NO by inhibiting PDE5, which is responsible for degradation of cGMP in the corpus cavernosum.
When sexual stimulation causes local release of NO, inhibition of PDE5 by sildenafil causes increased levels of cGMP in the corpus cavernosum, resulting in smooth muscle relaxation and inflow of blood to the corpus cavernosum.
Sildenafil at recommended doses has no effect in the absence of sexual stimulation.
Studies in vitro have shown that sildenafil is selective for PDE5.
Its effect is more potent on PDE5 than on other known phosphodiesterases (10-fold for PDE 6, >80-fold for PDE1, >700-fold for PDE2, PDE3 and PDE4, PDE7-PDE11).
The approximately 4,000-fold selectivity for PDE5 versus PDE3 is important because PDE3 is involved in control of cardiac contractility.
Clinical Studies: Cardiac: Single oral doses of sildenafil up to 100 mg produced no clinically relevant changes in the ECGs of normal male volunteers.
The mean maximum decreases in supine systolic blood pressure following 100 mg oral dosing was 8.3 mmHg. The corresponding change in supine diastolic blood pressure was 5.3 mmHg.
Larger but similarly transient effect on blood pressure was recorded among patients receiving concomitant nitrates (see Contraindications and Interactions).
In a study of the hemodynamic effects of a single oral 100mg dose of sildenafil in 14 patients with severe coronary artery disease (CAD) (>70% stenosis of at least 1 coronary artery), the mean resting systolic and diastolic blood pressures decreased by 7% and 6%, respectively compared to baseline. Mean pulmonary systolic blood pressure decreased by 9%. Sildenafil showed no effect on cardiac output, and did not impair blood flow through the stenosed coronary arteries and resulted in improvement (approximately 13%) in adenosine-induced coronary flow reserve (in both stenosed and reference arteries).
In a double-blind, placebo-controlled trial, 144 patients with erectile dysfunction and stable angina, who were taking their regular antianginal medications (except nitrates) were exercised until limiting angina occurred. The duration of treadmill exercise was statistically significantly longer (19.9 sec; 95% confidence interval: 0.9-38.9 sec) in the evaluable patients who had taken a single dose of sildenafil 100 mg compared to patients who had taken a single dose of placebo. The mean exercise times (adjusted for baseline) to the onset of limiting angina were 423.6 and 403.7 sec for sildenafil and placebo, respectively.
A randomized, double-blind, placebo-controlled, flexible-dose study (sildenafil up to 100 mg) in males (N=568) with erectile dysfunction and arterial hypertension taking ≥2 antihypertensive agents was conducted. Sildenafil improved the erections in 71% of men compared to 18% in the placebo group and 62% of attempts at sexual intercourse were successful with sildenafil compared to 26% on placebo. The incidence of adverse events was consistent with observations in other patient populations, as well as in the subjects taking ≥3 antihypertensive agents.
Visual: Mild and transient differences in colour discrimination (blue/green) were detected in some subjects using the Farnsworth-Munsell 100 hue test at 60 min following a 100 mg dose, with no effects evident after 120 min post-dose. The postulated mechanism for this change in colour discrimination is related to inhibition of PDE6, which is involved in the phototransduction cascade of the retina. In vitro studies show that sildenafil is 10-fold less potent against PDE6 than PDE5. Sildenafil has no effect on visual acuity, contrast sensitivity, electroretinograms, intraocular pressure or pupillometry.
In a placebo-controlled, crossover study of patients with documented early age-related macular degeneration (n=9), sildenafil (single dose of 100 mg) was well-tolerated and demonstrated no clinically significant changes in the visual tests conducted (visual acuity, Amsler grid, color discrimination, simulated traffic light, Humphrey perimeter and photostress).
Efficacy: The efficacy and safety of sildenafil was evaluated in 21 randomized, double-blind, placebo-controlled trials of up to 6 months duration. Sildenafil was administered to >3,000 patients aged 19-87, with ED of various etiologies (organic, psychogenic, mixed). The efficacy was evaluated by global assessment question, diary of erections, the international index of erectile function (IIEF, a validated sexual function questionnaire) and a partner questionnaire.
Sildenafil efficacy, determined as the ability to achieve and maintain an erection sufficient for sexual intercourse, was demonstrated in all 21 studies and was maintained in long-term extension studies (1 year). In fixed dose studies, the proportions of patients reporting that treatment improved their erections were 62% (25 mg), 74% (50 mg) and 82% (100 mg) compared to 25% on placebo. In addition to improvements in erectile dysfunction, analysis of the IIEF showed that sildenafil treatment also improved the domains of orgasm, satisfaction with intercourse and overall satisfaction.
Across all trials, the proportions of patients reporting improvement on sildenafil were 59% of diabetic patients, 43% of radical prostatectomy patients and 83% of patients with spinal cord injury (vs 16%, 15% and 12% on placebo, respectively).
Pharmacokinetics: Sildenafil pharmacokinetics are dose-proportional over the recommended dose range.
It is eliminated predominantly by hepatic metabolism (mainly cytochrome P450 3A4) and is converted to an active metabolite with properties similar to the parent, sildenafil.
Absorption: Sildenafil is rapidly absorbed after oral administration, with mean absolute bioavailability of 41% (range 25-63%).
Sildenafil inhibits the human PDE5 enzyme in vitro by 50% at a concentration of 3.5 nM. In man, the mean maximum free plasma concentration of sildenafil following a single oral dose of 100 mg is approximately 18 ng/mL or 38 nM.
Maximum observed plasma concentrations are reached within 30-120 min (median 60 min) of oral dosing in the fasted state.
Film-Coated Tablets: When sildenafil film-coated tablets are taken with high fat meal, the rate of absorption of sildenafil is reduced, with a mean delay in Tmax of 60 min and a mean reduction in Cmax of 29% however, the extent of absorption was not significantly affected (AUC decreased by 11%).
Distribution: The mean steady-state volume of distribution (Vss) for sildenafil is 105 L, indicating distribution into the tissues.
Sildenafil and its major circulating N-desmethyl metabolite are both approximately 96% bound to plasma proteins.
Protein binding is independent of total drug concentrations.
Based upon measurements of sildenafil in semen of healthy volunteers 90 min after dosing, <0.0002% (average 188 ng) of the administered dose may appear in the semen of patients.
Metabolism: Sildenafil is cleared predominantly by the CYP3A4 (major route) and CYP2C9 (minor route) hepatic microsomal isoenzymes.
The major circulating metabolite results from N-demethylation of sildenafil and is itself further metabolized.
This metabolite has a PDE selectivity profile similar to sildenafil and an in vitro potency for PDE5 approximately 50% of the parent drug.
In healthy volunteers, plasma concentrations of this metabolite are approximately 40% of those seen for sildenafil.
The N-desmethyl metabolite is further metabolised, with a terminal half life of approximately 4 hrs.
Elimination: The total body clearance of sildenafil is 41 L/hr with a resultant terminal phase half life of 3-5 hrs. After either oral or IV administration, sildenafil is excreted as metabolites predominantly in the faeces (approximately 80% of administered oral dose) and to a lesser extent in the urine (approximately 13% of administered oral dose).
Special Populations: Elderly: Healthy elderly volunteers (≥65 years) had a reduced clearance of sildenafil, resulting in approximately 90% higher plasma concentrations of sildenafil and the active N-desmethyl metabolite compared to those seen in healthy younger volunteers (18-45 years). Due to age-differences in plasma protein binding, the corresponding increase in free sildenafil plasma concentration was approximately 40%.
Renal Insufficiency: In volunteers with mild [creatinine clearance (CrCl)= 50-80 mL/min] and moderate (CrCl= 30-49 mL/min) renal impairment, the pharmacokinetics of a single oral dose of sildenafil (50 mg) were not altered.
In volunteers with severe (CrCl=<30 mL/min) renal impairment, sildenafil clearance was reduced, resulting in approximately doubling of AUC (100%) and Cmax (88%) compared to age-matched volunteers with no renal impairment (see Dosage & Administration).
In addition, N-desmethyl metabolite AUC and Cmax values were significantly increased 200% and 79% respectively in subjects with severe renal impairment compared to subjects with normal renal function.
Hepatic Insufficiency: In volunteers with hepatic cirrhosis (Child-Pugh A and B), sildenafil clearance was reduced, resulting in increases in AUC (85%) and Cmax (47%) compared to age-matched volunteers with no hepatic impairment (see Dosage & Administration). The pharmacokinetics of sildenafil in patients with severely impaired hepatic function (Child Pugh class C) have not been studied.
Toxicology: Preclinical Safety Data: Non-clinical data revealed no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential and toxicity to reproduction.
Treatment of men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.
In order for Olvion to be effective, sexual stimulation is required.
Adults: Recommended Dose: 50 mg taken as needed approximately 1 hr before sexual activity.
Based on effectiveness and tolerance, the dose may be increased to a maximum recommended dose of 100 mg or decreased to 25 mg. The maximum recommended daily dose is 100 mg. The maximum recommended dosing frequency is once per day.
Patients with Impaired Renal Function: Dosage adjustments are not required in patients with mild to moderate renal impairment [creatinine clearance (CrCl)=30-80 mL/min].
Since sildenafil clearance is reduced in patients with severe renal impairment (CrCl <30 mL/min) a 25 mg dose should be considered.
Patients with Impaired Hepatic Function: Since sildenafil clearance is reduced in patients with hepatic impairment (eg, cirrhosis) a 25 mg dose should be considered.
Patients Using Other Medication: Given the extent of the interaction with patients receiving concomitant therapy with ritonavir (see Interactions), co-administration with ritonavir is not advised. If ritonavir is co-administered with sildenafil, it is recommended not to exceed a maximum single dose of 25 mg of sildenafil in a 48-hr period.
A starting dose of 25 mg should be considered in patients receiving concomitant treatment with the CYP3A4 inhibitors (eg, erythromycin, saquinavir, ketoconazole, itraconazole) (see Interactions).
In order to minimize the potential for developing postural hypotension, patients should be stable on α-blocker therapy prior to initiating sildenafil treatment. In addition, initiation of sildenafil at lower doses should be considered (see Precautions and Interactions).
Elderly Men:
Since sildenafil clearance is reduced in elderly patients, a 1st dose of 25 mg should be considered.
Administration: Sildenafil tablets are for oral administration.
In studies with healthy volunteers of single doses up to 800 mg, adverse events were similar to those seen at lower doses, but the incidence rates and severities were increased.
In cases of overdose, standard supportive measures should be adopted as required. Renal dialysis is not expected to accelerate clearance as sildenafil is highly bound to plasma proteins and not eliminated in the urine.
Hypersensitivity to sildenafil citrate or to any of the excipients of Olvion.
Consistent with its known effects on the nitric oxide/cyclic guanosine monophosphate (cGMP) pathway (see Pharmacology: Pharmacodynamics under Actions), sildenafil was shown to potentiate the hypotensive effects of nitrates and its co-administration with nitric oxide donors (eg, amyl nitrite) or nitrates in any form is therefore contraindicated.
Agents for the treatment of erectile dysfunction, including sildenafil, should not be used in men for whom sexual activity is inadvisable (eg, patients with severe cardiovascular disorders eg, unstable angina or severe cardiac failure).
Olvion is contraindicated in patients who have loss of vision in one eye because of non-arteritic anterior ischaemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous PDE5 inhibitor exposure (see Precautions).
The safety of sildenafil has not been studied in the following sub-groups of patients and its use is therefore contraindicated: severe hepatic impairment, hypotension (blood pressure <90/50 mmHg), recent history of stroke or myocardial infarction and known hereditary degenerative retinal disorders eg, retinitis pigmentosa (a minority of these patients has genetic disorders of retinal phosphodiesterases).
A thorough medical history and physical examination should be undertaken to diagnose erectile dysfunction, determine potential underlying causes and identified appropriate treatment.
There is a degree of cardiac risk associated with sexual activity; therefore, physicians may wish to consider the cardiovascular status of their patients prior to initiating any treatment for erectile dysfunction.
Agents for the treatment of erectile dysfunction should not be used in men for whom sexual activity is inadvisable.
Serious cardiovascular events, including myocardial infarction, sudden cardiac death, ventricular arrhythmia, cerebrovascular haemorrhage and transient ischaemic attack have been reported post-marketing in temporal association with the use of sildenafil for erectile dysfunction.
Most, but not all, of these patients had preexisting cardiovascular risk factors. Many of these events were reported to occur shortly after the use of sildenafil without sexual activity. Others were reported to have occurred hours to days after the use of sildenafil and sexual activity. It is not possible to determine whether these events are related directly to sildenafil, to sexual activity, to the patient’s underlying cardiovascular disease, to a combination of these factors or to other factors.
In clinical trials, sildenafil has been shown to have systemic vasodilatory properties that result in transient decreases in blood pressure (see Pharmacology: Pharmacodynamics under Actions). This is of little or no consequence in most patients. However, prior to prescribing sildenafil, physicians should carefully consider whether their patients with certain underlying conditions could be adversely affected by such vasodilatory effects, especially in combination with sexual activity. Patients with increased susceptibility to vasodilators include those with left ventricular outflow obstruction (eg, aortic stenosis, hypertrophic obstructive cardiomyopathy) or those with the rare syndrome of multiple system atrophy manifesting as severely impaired autonomic control of blood pressure.
Non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision or loss of vision, has been reported rarely post-marketing with the use of all PDE5 inhibitors, including sildenafil. Most of these patients had risk factors eg, low cup to disc ratio ("crowded disc"), age >50, diabetes, hypertension, coronary artery disease, hyperlipidemia and smoking. No causal relationship has been made between use of PDE5 inhibitors and NAION. Physicians should discuss with patients the increased risk of NAION in individuals who have already experienced NAION. The patients should be advised that in case of sudden visual loss, to stop taking sildenafil and consult a physician immediately.
Prolonged erections >4 hrs and priapism (erections >6 hrs) have been reported infrequently since market approval of sildenafil. In the event of an erection that persists >4 hrs, the patient should seek immediate medical assistance. If priapism is not treated immediately, penile tissue damage and permanent loss of potency could result.
Caution is advised when sildenafil is administered to patients taking an α-blocker, as the co-administration may lead to symptomatic hypotension in a few susceptible individuals (see Interactions). In order to minimize the potential for developing postural hypotension, patients should be hemodynamically stable on α-blocker therapy prior to initiating sildenafil treatment. Initiation of sildenafil at lower doses should be considered (see Dosage & Administration). In addition, physicians should advise patients what to do in the event of postural hypotensive symptoms.
A minority of patients with the inherited condition retinitis pigmentosa have genetic disorders of retinal phosphodiesterases. There is no safety information on the administration of sildenafil to patients with retinitis pigmentosa, therefore, sildenafil should be administered with caution to these patients.
In vitro studies with human platelets indicate that sildenafil potentiates the antiaggregatory effect of sodium nitroprusside (a nitric oxide donor). There is no safety information on the administration of sildenafil to patients with bleeding disorders or active peptic ulceration, therefore sildenafil should be administered with caution to these patients.
Agents for the treatment of erectile dysfunction should be used with caution in patients with anatomical deformation of the penis (eg, angulation, cavernosal fibrosis or Peyronie’s disease) or in patients who have conditions which may predispose them to priapism (eg, sickle cell anemia, multiple myeloma or leukemia).
Sildenafil should be used with caution in patients with resting hypertension (BP >170/110), patients who have suffered life-threatening arrhythmia within the last 6 months and patients with history of cardiac failure or coronary artery disease causing unstable angina.
The safety and efficacy of combinations of sildenafil with other treatments for erectile dysfunction have not been studied and the use of such combinations is not recommended.
Sudden decrease or loss of hearing has been reported in a small number of postmarketing and clinical trials cases with the use of all PDE5 inhibitors, including sildenafil. Most of these patients had risk factors for sudden decrease or loss of hearing. No causal relationship has been made between the use of PDE5 inhibitors and sudden decrease or loss of hearing. In case of sudden decrease or loss of hearing, patients should be advised to stop taking sildenafil and consult a physician promptly.
The film coating of the Olvion tablet contains lactose. Olvion should not be administered to men with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
Effects on the Ability to Drive or Operate Machinery: No studies on the effects on the ability to drive and use machines have been performed.
As dizziness and altered vision were reported in clinical trials with sildenafil, patients should be aware of how they react to Olvion, before driving or operating machinery.
Use in pregnancy & lactation: Olvion is not indicated for use by women.
No relevant adverse effects were found in reproduction studies in rats and rabbits following oral administration of sildenafil.
Use in children: Olvion is not indicated for use in children <18 years.
Olvion is not indicated for use by women. No relevant adverse effects were found in reproduction studies in rats and rabbits following oral administration of sildenafil.
The adverse events were generally transient and mild to moderate in nature.
In fixed-dose studies, the incidence of some adverse events increased with dose.
The nature of the adverse events in flexible-dose studies, which more closely reflect the recommended dosage regimen, was similar to that for fixed-dose studies.
The most commonly reported adverse reactions were headache and flushing. (See Tables 1 and 2.)
Click on icon to see table/diagram/image
Click on icon to see table/diagram/image
At doses above the recommended dose range, adverse events were similar to those detailed above but generally were reported more frequently.
In an analysis of double blind placebo controlled clinical trials encompassing >700 person-years of observation on placebo and >1300 person-years on sildenafil, there were no differences in the incidence rate of myocardial infarction (MI) or in the rate of cardiovascular mortality for patients receiving sildenafil compared to those receiving placebo. The rates of MI were 1.1 per 100 person-years for men receiving sildenafil and for those receiving placebo. The rates of cardiovascular mortality were 0.3 per 100 person-years for men receiving sildenafil and those receiving placebo.
The Following Adverse Reactions were Reported During Post-Marketing Surveillance: Immune System Disorders: Hypersensitivity reaction (including skin rash).
Nervous System Disorders: Seizure, seizure recurrence.
Cardiac Disorders: Tachycardia.
Vascular Disorders: Hypotension, syncope, epistaxis.
Gastrointestinal Disorders: Vomiting.
Eye Disorders: Eye pain, red eyes/bloodshot eyes.
Reproductive System and Breast Disorders: Prolonged erection and/or priapism.
Effects of Other Medicinal Products on Sildenafil: In Vitro Studies: Sildenafil metabolism is principally mediated by the cytochrome P450 (CYP) isoforms 3A4 (major route) and 2C9 (minor route). Therefore, inhibitors of these isoenzymes may reduce sildenafil clearance.
In Vivo Studies: Population pharmacokinetic analysis of clinical trial data indicated a reduction in sildenafil clearance when co-administered with CYP3A4 inhibitors (eg, ketoconazole, erythromycin, cimetidine).
Cimetidine (800 mg), a cytochrome P450 inhibitor and a non-specific CYP3A4 inhibitor, caused a 56% increase in plasma sildenafil concentrations when co-administered with sildenafil (50 mg) to healthy volunteers.
When a single 100 mg dose of sildenafil was administered with erythromycin, a specific CYP3A4 inhibitor, at steady state (500 mg twice daily for 5 days), there was a 182% increase in sildenafil systemic exposure area under the curve (AUC). In addition, co-administration of the HIV protease inhibitor saquinavir, also a CYP34A inhibitor, at steady state (1200 mg 3 times daily) with sildenafil (100 mg single dose) resulted in a 140% increase in sildenafil peak plasma concentration (Cmax) and a 210% increase in sildenafil AUC. Sildenafil had no effect on saquinavir pharmacokinetics (see Dosage & Administration). Stronger CYP3A4 inhibitors eg, ketoconazole and itraconazole would be expected to have greater effects.
Co-administration of the HIV protease inhibitor ritonavir, which is a highly potent P450 inhibitor, at steady state (500 mg twice daily) with sildenafil (100 mg single dose) resulted in a 300% (4-fold) increase in sildenafil Cmax and a 1000% (11-fold) increase in sildenafil plasma AUC. At 24 hrs, the plasma levels of sildenafil were still approximately 200 ng/mL, compared to approximately 5 ng/mL when sildenafil was administered alone. This is consistent with ritonavir's marked effects on a broad range of P450 substrates. Sildenafil had no effect on ritonavir pharmacokinetics (see Dosage & Administration).
Grapefruit juice being a weak inhibitor of CYP3A4 gut wall metabolism may give rise to modest increase in plasma levels of sildenafil.
When the dose of sildenafil for subjects receiving potent CYP3A4 inhibitors was administered as recommended, the maximum free plasma sildenafil concentration did not exceed 200 nM for any individual and was consistently well tolerated. Single doses of antacid (magnesium hydroxide/aluminium hydroxide) did not affect the bioavailability of sildenafil.
Pharmacokinetic data from patients in clinical trials showed no effect on sildenafil pharmacokinetics of CYP2C9 inhibitors (eg, tolbutamide, warfarin), CYP2D6 inhibitors (eg, selective serotonin reuptake inhibitors, tricyclic antidepressants), thiazide and related diuretics, angiotensin converting enzyme inhibitors and calcium channel blockers.
In normal healthy male volunteers, there was no evidence of an effect of azithromycin (500 mg daily for 3 days) on the AUC, Cmax, Tmax, elimination rate constant or subsequent half-life of sildenafil or its major circulating metabolite.
Effects of Sildenafil on Other Medicinal Products: In Vitro Studies: Sildenafil is a weak inhibitor of the cytochrome P450 isoforms 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 (IC50 >150 micrometer).
Given sildenafil Cmax of approximately 1 micrometer after recommended doses, it is unlikely that sildenafil will alter the clearance of substrates of these isoenzymes.
In Vivo Studies: Sildenafil was shown to potentiate the hypotensive effect of acute and chronic nitrates. Therefore, use of nitric oxide donors, organic nitrates or organic nitrites in any form either regularly or intermittently with sildenafil is contraindicated (see Contraindications).
In 3 specific drug-drug interaction studies, the α-blocker doxazosin (4 mg and 8 mg) and sildenafil (25 mg, 50 mg or 100 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy. In these study populations, mean additional reductions of supine blood pressure of 7/7 mmHg, 9/5 mmHg and 8/4 mmHg, and mean additional reductions of standing blood pressure of 6/6 mmHg, 11/4 mmHg and 4/5 mmHg, respectively, were observed. When sildenafil and doxazosin were administered simultaneously to patients stabilized on doxazosin therapy, there were infrequent reports of patients who experienced symptomatic postural hypotension. These reports included dizziness and lightheadedness, but not syncope. Concomitant administration of sildenafil to patients taking α-blocker therapy may lead to symptomatic hypotension in a few susceptible individuals (see Dosage & Administration and Precautions).
No significant interactions were shown when sildenafil (50mg) was co-administered with tolbutamide (250 mg) or warfarin (40 mg), both of which are metabolised by CYP2C9.
Sildenafil (100 mg) did not affect the steady state pharmacokinetics of the HIV protease inhibitors, saquinavir and ritonavir, both of which are CYP3A4 substrates (see Effects of Other Medicinal Products on Sildenafil).
Sildenafil (50 mg) did not potentiate the increase in bleeding time caused by aspirin (150 mg).
Sildenafil (50 mg) did not potentiate the hypotensive effects of alcohol in healthy volunteers with mean maximum blood alcohol levels of 0.08% (80 mg/dL).
No interaction was seen when sildenafil (100 mg) was co-administered with amlodipine in hypertensive patients. The mean additional reduction on supine blood pressure was 8 mmHg systolic and 7 mmHg diastolic.
Analysis of the safety database showed no difference in the side effect profile in patients taking sildenafil with and without antihypertensive medication.
Incompatibilities: Not applicable.
G04BE03 - sildenafil ; Belongs to the class of drugs used in erectile dysfunction.
Sign Out
Click on icon to see table/diagram/image
Click on icon to see table/diagram/image
